CJC-1295: GHRH Analogue Research Guide (2026)
Last updated
Introduction (research-only scope)
CJC-1295 is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone, modified to resist enzymatic breakdown. It exists in two forms that are frequently confused, with and without a drug affinity complex, and this guide separates them clearly, alongside the mechanism, the published evidence and how to verify research-grade material.
Research use only. The material described here is a laboratory reagent for in-vitro research by qualified professionals. It is not a medicine, supplement, cosmetic ingredient or veterinary product, is not for human or animal use, and nothing on this page is medical advice or a claim of effect in any person.
What is CJC-1295?
The form supplied here (molecular mass 3367.9, CAS 863288-34-0) is the tetrasubstituted GRF(1-29) analogue, often called modified GRF(1-29) or CJC-1295 without DAC. The DAC version carries an additional maleimide group that binds albumin and extends circulation time by days; it has a different mass (3775.4) and is catalogued separately as CJC-1295 DAC. Our comparison CJC-1295 vs CJC-1295 DAC sets the two side by side; treating published data on one as if it applied to the other is the most common error with this compound.
How the reported mechanism works
GHRH receptor agonism
CJC-1295 acts on the GHRH receptor in the anterior pituitary, the physiological pathway that stimulates growth hormone release, and its four amino-acid substitutions slow degradation by dipeptidyl peptidase-4.
A different receptor from ghrelin mimetics
Secretagogues such as ipamorelin act on GHS-R1a instead, which is why the two classes are studied together in receptor-interaction designs; see Ipamorelin vs CJC-1295.
What the published evidence covers
The reference clinical pharmacology study, published in the Journal of Clinical Endocrinology and Metabolism in 2006, reported prolonged stimulation of growth hormone and IGF-I secretion in healthy adults. That study used the DAC form, which is exactly why the distinction above matters: it is not evidence about the non-DAC analogue supplied here. Development did not lead to an approved product, and no marketing authorisation exists.
How to verify a CJC-1295 research peptide is real and pure
Two tests answer two different questions: mass spectrometry confirms identity (expected molecular mass 3367.9), HPLC quantifies purity. Our specification is at least 98%. Check the batch number printed on your vial against the lab reports archive: where a batch has been tested, its report is published there and links to the testing laboratory’s own verification page. If your batch is not listed yet, ask us for its documentation before use; a “typical” certificate is not evidence for a specific vial. See how to read a certificate of analysis.
Storage and reconstitution
Store the lyophilised material sealed, dry and protected from light at 2 to 8 °C for routine laboratory use, colder for long-term archiving. After reconstitution with bacteriostatic water, keep refrigerated and use within the window your protocol defines; repeated freeze-thaw cycles degrade peptides. General handling for all our reagents is in the peptide storage protocol.
Regulatory status
CJC-1295 is not an authorised medicine in the European Union, the United Kingdom or the United States. It is named on the WADA Prohibited List (section S2, growth hormone releasing factors, among the GHRH analogues), prohibited at all times, so material must not be used in the context of sport in any form; the live list is the binding reference. Research-grade material supplied here is not a medicine and is for in-vitro laboratory use only. The wider framework, including anti-doping status, is described in the peptide risk profile.
Why labs choose our CJC-1295
Batch-numbered vials, published reports where a batch has been tested, shipping from an EU warehouse with tracking (no customs inside the EU) and prices shown with VAT included. Product page: CJC-1295 5 mg. Country-by-country sourcing questions are covered in the buyer guide Buy CJC-1295 in Europe.
References
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PubMed 16352683
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PubMed 9849822